Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of travelers' diarrhea

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
C M RademakerJ Verhoef

Abstract

To determine the efficacy, safety and effect on fecal flora of ciprofloxacin in the prevention of travelers' diarrhea, 54 volunteers traveling to Tunisia were randomized in a double-blind manner to receive either 500 mg ciprofloxacin or a placebo once daily for one week. Results of 53 volunteers were available for evaluation of efficacy. One of 25 subjects (4%) receiving ciprofloxacin versus 18 of 28 subjects (64%) in the placebo group experienced travelers' diarrhea (p less than 0.0001). The protection offered by ciprofloxacin was 94%. In one volunteer taking ciprofloxacin, prophylaxis was terminated due to sunburn with blistering. Among 41 subjects reporting sunburn, no statistical difference was observed between the two treatment groups in the percentage of body surface area of sunburn. Quantitative feces cultures revealed a marked decrease in the number of gram-negative organisms in volunteers receiving ciprofloxacin and a significant increase in the number of Escherichia coli in the placebo group. Five weeks after return, the aerobic bacterial flora of both treatment groups showed the pre-travel pattern.

References

Jun 10, 1976·The New England Journal of Medicine·M H MersonE J Gangarosa
Dec 5, 1987·Lancet·H C Neu
Oct 1, 1987·The Journal of Antimicrobial Chemotherapy·J WiströmG Englund
Mar 13, 1987·JAMA : the Journal of the American Medical Association·H L DuPontF J de la Cabada
Apr 3, 1982·Lancet
Nov 1, 1981·The Journal of Infectious Diseases·R W RyderR B Sack
Jan 1, 1983·Annals of Internal Medicine·C D EricssonD J Evans
Mar 4, 1983·JAMA : the Journal of the American Medical Association·R SteffenM Schär

❮ Previous
Next ❯

Citations

May 1, 1993·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I M HoepelmanJ Verhoef
Aug 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C M RademakerJ Verhoef
Jan 1, 1993·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H P EndtzR P Mouton
Jul 21, 2009·Current Gastroenterology Reports·Emily Singh, David Redfield
Jan 21, 2006·Current Treatment Options in Gastroenterology·Andrew W DuPont, Herbert L DuPont
Jan 1, 1993·International Journal of Antimicrobial Agents·E G Obot, H L Dupont
Jun 1, 1993·Baillière's Clinical Gastroenterology·R C Arduino, H L DuPont
Sep 28, 1998·Biochimica Et Biophysica Acta·D C Hooper
Nov 3, 2005·Nature Clinical Practice. Gastroenterology & Hepatology·Herbert L DuPont
Jun 24, 1993·The New England Journal of Medicine·H L DuPont, C D Ericsson
Nov 4, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Herbert L DuPontFrancisco Martinez-Sandoval
Jul 14, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Herbert L DuPont
Jul 19, 2006·Clinical Microbiology Reviews·David J Diemert
Dec 1, 1996·British Journal of Sports Medicine·A C Anderson
Feb 7, 1991·The New England Journal of Medicine·D C Hooper, J S Wolfson
Apr 24, 2010·Journal of Travel Medicine·Francisco Martinez-SandovalHerbert L DuPont
Jun 23, 2009·Journal of Travel Medicine·Herbert L DuPontThomas Weinke
Jun 23, 2009·Journal of Travel Medicine·Charles D EricssonUNKNOWN International Society of Travel Medicine Clinical Research Group
Sep 1, 1994·Journal of Travel Medicine·D N Taylor
Jun 1, 1994·Journal of Travel Medicine·H L DuPont, F M Khan
Feb 21, 2008·Alimentary Pharmacology & Therapeutics·H L DuPont
Sep 1, 1996·Gastroenterology Clinics of North America·M D Nettleman
Apr 12, 2003·Primary Care·David J Diemert
Sep 26, 2013·Travel Medicine and Infectious Disease·Lukasz KrokowiczTomasz Banasiewicz
Jul 31, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S AnandS K Tomar
Nov 17, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David R HillUNKNOWN Infectious Diseases Society of America
Sep 9, 2005·Current Opinion in Infectious Diseases·Herbert L DuPont
Jan 1, 1992·Scandinavian Journal of Infectious Diseases·B WretlindB Kaijser
Nov 21, 2018·Tropical Diseases, Travel Medicine and Vaccines·Ajib DiptyanusaWatcharapong Piyaphanee
Feb 1, 2003·Paediatrics & Child Health·Pierre J Plourde
Nov 1, 1990·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·T H Holtz, M D Nettleman
May 21, 2004·Journal of Gastroenterology and Hepatology·Anna C Casburn-Jones, Michael J G Farthing
Jun 27, 2000·Gastroenterology·S Banerjee, J T LaMont

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.